ES2256896T3 - Acidos nucleicos para uso en terapia genica que implica la expresion de genes en celulas intestinales. - Google Patents

Acidos nucleicos para uso en terapia genica que implica la expresion de genes en celulas intestinales.

Info

Publication number
ES2256896T3
ES2256896T3 ES97942543T ES97942543T ES2256896T3 ES 2256896 T3 ES2256896 T3 ES 2256896T3 ES 97942543 T ES97942543 T ES 97942543T ES 97942543 T ES97942543 T ES 97942543T ES 2256896 T3 ES2256896 T3 ES 2256896T3
Authority
ES
Spain
Prior art keywords
protein
cells
dna
intestinal
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942543T
Other languages
English (en)
Spanish (es)
Inventor
Michael German
Ira D. Goldfine
Stephen S. Rothman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2256896T3 publication Critical patent/ES2256896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES97942543T 1996-09-19 1997-09-18 Acidos nucleicos para uso en terapia genica que implica la expresion de genes en celulas intestinales. Expired - Lifetime ES2256896T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US717084 1991-06-18
US08/717,084 US6225290B1 (en) 1996-09-19 1996-09-19 Systemic gene therapy by intestinal cell transformation

Publications (1)

Publication Number Publication Date
ES2256896T3 true ES2256896T3 (es) 2006-07-16

Family

ID=24880656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97942543T Expired - Lifetime ES2256896T3 (es) 1996-09-19 1997-09-18 Acidos nucleicos para uso en terapia genica que implica la expresion de genes en celulas intestinales.

Country Status (10)

Country Link
US (4) US6225290B1 (https=)
EP (1) EP0939590B1 (https=)
JP (1) JP2001502303A (https=)
AT (1) ATE320186T1 (https=)
AU (1) AU729457B2 (https=)
CA (1) CA2264744A1 (https=)
DE (1) DE69735496T2 (https=)
DK (1) DK0939590T3 (https=)
ES (1) ES2256896T3 (https=)
WO (1) WO1998011779A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999049029A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BR9909918A (pt) * 1998-05-06 2000-12-26 Upjohn Co Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
US6503887B1 (en) * 1999-02-19 2003-01-07 Matthew During Peroral gene therapy of diabetes and obesity
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
DK1159415T3 (da) * 1999-03-04 2010-05-03 Revivicor Inc Genetisk modifikation af somatiske celler og anvendelse deraf
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
DK1274464T3 (da) 2000-03-13 2012-01-23 Engene Inc Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
GB0010630D0 (en) * 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002000939A2 (en) 2000-06-28 2002-01-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20020151068A1 (en) * 2001-01-03 2002-10-17 Board Of Regents, The University Of Texas System Compositions and methods for the diagnosis and treatment of organophosphate toxicity
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
AU2002338345A1 (en) * 2001-04-04 2002-10-21 Digital Gene Technologies, Inc. Genes expressed in intestinal epithelium and peyer's patch m cells
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
EP1404713A4 (en) * 2001-05-24 2004-09-22 Human Dna Technology Inc NEW KERATINOCYTE GROWTH FACTOR 2 ANALOG IN HAIR FOLLICULES
AU2002365188A1 (en) * 2001-11-07 2003-07-30 Musc Foundation For Research Development Nucleic acid delivery and expression
US20030135195A1 (en) * 2002-01-16 2003-07-17 Oscar Jimenez Highly lubricious hydrophilic coating utilizing dendrimers
DE60336754D1 (de) 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
WO2003104439A2 (en) * 2002-03-12 2003-12-18 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
DE60336063D1 (de) * 2002-05-31 2011-03-31 Childrens Hosp Medical Center Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
CA2503437A1 (en) * 2002-10-24 2004-05-06 Biogen Idec Ma Inc. High expression locus vector based on ferritin heavy chain gene locus
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005032574A1 (en) * 2003-10-03 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP2011504366A (ja) * 2007-11-26 2011-02-10 プラント バイオサイエンス リミティド エンドリシン活性を有する新規ポリペプチド及びその使用
EP2296683B1 (en) 2008-06-03 2017-01-25 University Of Rochester AvrA PROTEIN FOR TREATING INFLAMMATORY INTESTINAL DISEASE AND MANAGING SYMPTOMS THEREOF
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
EP2440582B1 (en) 2009-06-09 2018-11-07 Children's Hospital Medical Center Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
US20160160229A1 (en) * 2014-12-09 2016-06-09 THC Farmaceuticals, Inc. Methods of producing antibody-rich cannabis and honeysuckle plants
EP3600397A4 (en) 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
US20230051811A1 (en) * 2019-12-20 2023-02-16 Translate Bio, Inc Rectal delivery of messenger rna

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
WO1990005787A1 (en) 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
WO1994016057A1 (en) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Enhancer sequence for modulating expression in epithelial cells
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
US5681744A (en) * 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
JPH11507340A (ja) 1995-06-07 1999-06-29 アルザ コーポレイション 遺伝子構築物の経口送出
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation

Also Published As

Publication number Publication date
DK0939590T3 (da) 2006-07-24
US20050026863A1 (en) 2005-02-03
CA2264744A1 (en) 1998-03-26
EP0939590A1 (en) 1999-09-08
EP0939590B1 (en) 2006-03-15
ATE320186T1 (de) 2006-04-15
US6258789B1 (en) 2001-07-10
WO1998011779A1 (en) 1998-03-26
DE69735496T2 (de) 2006-09-21
US6831070B2 (en) 2004-12-14
EP0939590A4 (en) 2002-09-04
AU4422197A (en) 1998-04-14
US6225290B1 (en) 2001-05-01
US20020039574A1 (en) 2002-04-04
AU729457B2 (en) 2001-02-01
DE69735496D1 (de) 2006-05-11
JP2001502303A (ja) 2001-02-20

Similar Documents

Publication Publication Date Title
ES2256896T3 (es) Acidos nucleicos para uso en terapia genica que implica la expresion de genes en celulas intestinales.
ES2611007T3 (es) Análogos de insulina acilada, estabilizados frente a proteasas
US6004944A (en) Protein delivery by secretory gland expression
EP0726778B1 (en) Oral delivery system of chemically modified proteins g-csf
RU2627451C2 (ru) Противовоспалительные композиции
BR112015011583B1 (pt) Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
ES2374061T3 (es) Composiciones y métodos para la expresión regulada de proteína en el intestino.
ES2228082T3 (es) Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados.
AU744279B2 (en) Protein delivery by secretory gland expression
Jena et al. Challenges and therapeutic approaches for the protein delivery system: a review
ES2372728T3 (es) Cicatrización de heridas mediante la administración de il-18 humana.
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
NAYAK International Journal of Pharmacy and Pharmaceutical Sciences